<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EQUI-PHAR - phenylbutazone injection </strong><br>Vedco, Inc.<br></p></div>
<h1>EQUI-PHAR
PHENYLBUTAZONE 20% INJECTION
200 mg/mL</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Horses Only</span><br><span class="Bold">CAUTION</span>: Federal law restricts this drug to use by or on the order of a licensed veterinarian.<br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION</span>: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> is probably related mainly to the compound's anti-inflammatory properties.  Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:</p>
<p><img alt="Formula label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5dd8b3b7-edfb-46f9-a7f2-b87a1ad06b6c&amp;name=Formula.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>BACKGROUND PHARMACOLOGY</h1>
<p class="First">Kuzell, <span class="Sup">1, 2, 3</span> Payne,<span class="Sup">4</span> Fleming,<span class="Sup">5</span> and Denko<span class="Sup">6</span> demonstrated clinical effectiveness of phenylbutazone in acute <span class="product-label-link" type="condition" conceptid="138845" conceptname="Rheumatism">rheumatism</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span> and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre,<span class="Sup">7</span> Domenjoz,<span class="Sup">8</span> Wilhelmi,<span class="Sup">9</span> and Yourish.<span class="Sup">10</span>  Lieberman <span class="Sup">11</span> reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculosketal system in dogs; including posterior <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> associated with intervertebral disc syndrome, painful <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and painful injuries to the limbs and joints. Joshua<span class="Sup">12</span> observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilvie and Sutter<span class="Sup">13</span> reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, posterior <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="138845" conceptname="Rheumatism">rheumatism</span>, and other conditions associated with lameness and musculoskeletal <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. <br></p>
<p>Camberos<span class="Sup">14</span> reported favorable results with phenylbutazone following intermittent treatment of Thoroughbred horses for <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> and chronic <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span> (e.g., <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of medial and distal bones of the hock, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> of stifle and hip, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span> of the spine, chronic hip <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span>, achronic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the trapezius muscles, and generalized <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>). Results were less favorable in cases of traumatism, muscle rupture, <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span> of the third phalanx. Sutter<span class="Sup">15</span> reported favorable response in chronic equine <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">For relief of inflammatory conditions associated with the musculoskeletal system in horses.<br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug allergy</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<p class="First">Stop medication at the first sign of <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>. Authenticated cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in th total white count, relative decrease in granulocytes, or black or <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span>, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, specific anti-infective therapy is required.<br></p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">Store in refrigerator between 2<span class="Sup">o</span> - 8<span class="Sup">o</span>C (36<span class="Sup">o</span> - 46<span class="Sup">o</span>F)</span><br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">HORSES</span><br><span class="Bold">INTRAVENOUSLY</span><span class="Bold">:</span> 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.</p>
<p><span class="Bold">GUIDELINES TO SUCCESSFUL THERAPY</span><br>1.  Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.<br>2.  Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.<br>3.  In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.<br>4.  Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms. <br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">INJECTABLE</span>: <span class="Bold">For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL)</span> Each mL contians 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, Q.S.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.<br>2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.<br>3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 777:319, 1952.<br>4. Payne, R.W., Shetlar, M.R., Farr, C., Hellbaum, A.A., and Ishmael, W.K.T.: J.Lab. Clin. Med. 45:331, 1955.<br>5. Fleming, J. and @Will, G.: Ann Rheumat. Dis. 12:95, 1953.<br>6. Denko, C.W., and Rumi, D.: Amer. Practit. 6:1865, 1955.<br>7. Fabre, J. and Berger, A.: Semaine Hop. (Paris) 31:87, 1955.<br>8. Domenjoz, R., Theobald, W. and Morsdorf, K., Arzneimittel-Forsch. 5:488, 1955.<br>9 Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.<br>10. Yoursh, N., Paton, B., Brodie, B.B and <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span>, J.J.: AMA Arch. Ophth. 53:264, 1955.<br>11. Lieberman, L.L.: Jour. Amer. Vet. Med. Assoc. 125:128, 1954.<br>12. Joshua, J.O.: Vet. Rec. 68:60 (Jan 21), 1956.<br>13. Ogilvie, F.B. and Sutter, M.D.: Vet. Med 52:492-494, 1957.<br>14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38:9, 1956.<br>15. Sutter, M.F.: Vet Med. 53:83 (Feb.), 1958.<br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-11"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">For relief of inflammatory conditions associated with the musculoskeletal system in horses. <br></p>
<p><span class="Bold">Intravenous dosage (not subcutaneous or intramuscular use)</span>:</p>
<p><span class="Bold">Horses</span>: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.</p>
<p>Not for use in Horses intended for food.</p>
<p>See package outsert for additional information.</p>
<p><span class="Bold">ANADA 200-371, Approved by FDA</span></p>
<p><span class="Bold">Each mL contains:<br></span>Phenylbutazone ............................. 200 mg<br>Benzyl Alcohol Preservative .........10.45 mg<br>Sodium hydroxide to adjust pH to 9.5 to 10.0<br>Water For Injection ...............................q.s. <br><span class="Bold"></span></p>
<p><span class="Bold"><br></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<br><span class="Bold">FOR HORSES ONLY<br><br>KEEP OUT OF REACH OF CHILDREN<br><br>CAUTION</span>: Federal law restricts this drug to use by or on the order of a licensed veterinarian.<br><br><div class="Figure"><img alt="VED-Phenylbutazone Inj Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5dd8b3b7-edfb-46f9-a7f2-b87a1ad06b6c&amp;name=VED-Equi-Phar-12.jpg"></div>
<br><div class="Figure"><img alt="VED-Phenylbutazone Inj Label Onsert" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5dd8b3b7-edfb-46f9-a7f2-b87a1ad06b6c&amp;name=VED-Equi-Phar-Onsert-12.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EQUI-PHAR 		
					</strong><br><span class="contentTableReg">phenylbutazone injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50989-425</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENYLBUTAZONE</strong> (PHENYLBUTAZONE) </td>
<td class="formItem">PHENYLBUTAZONE</td>
<td class="formItem">200 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50989-425-12</td>
<td class="formItem">100 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANADA</td>
<td class="formItem">ANADA200371</td>
<td class="formItem">07/01/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Vedco, Inc.
							(021634266)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c1c99bc8-de23-49b8-82ab-b296045d2691</div>
<div>Set id: 5dd8b3b7-edfb-46f9-a7f2-b87a1ad06b6c</div>
<div>Version: 3</div>
<div>Effective Time: 20130114</div>
</div>
</div> <div class="DistributorName">Vedco, Inc.</div></p>
</body></html>
